HSBC noted that Biocon's QIP launched to repay debt will ease leverage; but, scaling and creating new biosimilars remains critical for the firm's turnaround.

HSBC has cut the target price on Biocon Ltd. from Rs 400 to Rs 390, as it sees negative impact on earnings per share due to the company's Rs 4,500-crore qualified institutional placement that ...

CHENNAI: Biocon Biologics, the biosimilars subsidiary of Biocon Ltd, said on Friday that Health Canada has granted a Notice of Compliance (NOC) for its age-related macular degeneration (AMD) drug ...

Biocon Ltd board approves $198.5 million acquisition of Biocon Biologics debentures from Goldman Sachs.

Indian drugmaker Biocon has abandoned plans to market generic versions of Novo Nordisk’s hot-selling diabetes and weight-loss drugs in China due to local competition, a senior executive said.

Ramy Ayad, Head of Canada at Biocon Biologics, stated: “This is a significant achievement for Biocon Biologics in Canada. With the approval of YESAFILI, we are delivering on our promise to ...

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd. , said:“The approval of YESAFILI by Health Canada-the first biosimilar to EYLEA® in Canada-is a proud moment for Biocon Biologics.

Biocon Shares Gain Amid High Volume, Up by 0.47% With the stock currently priced at Rs 350.85, Biocon's recent financial performance, high trading volume, and presence in major market indices ...

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch scheduled for July 4, 2025, targeting treatment of serious eye diseases.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said: "The approval of YESAFILI by Health Canada-the first biosimilar to EYLEA® in Canada-is a proud moment for Biocon Biologics. We are ...